Yi Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yi Cui has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Nuo Xu
Department of Ophthalmology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital
4 shared publications Li Huang
Department of Ophthalmology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
3 shared publicationsNuo Xu
2 shared publicationsAndrea Ludwig-Sengpiel
KLB Gesundheitsforschung Luebeck, Luebeck, Germany
1 shared publicationAnnabel Hogg
GSK, Stevenage, UK
1 shared publication- Anthony Cahn
GSK, Global Health Medicines, R&D Stevenage UK
1 shared publication
Latest Publications
- Open Access
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Identifying diagnostic biomarkers for glaucoma based on transcriptome combined with Mendelian randomization
Glaucoma poses a significant global health challenge, yet reliable biomarkers for its diagnosis and treatment remain scarce. This study employed Mendelian randomization (MR) and bioinformatics approaches to identify potential biomarkers for glaucoma. Using the GSE9944 dataset, differentially expressed genes (DEGs) were identified and analyzed through protein-protein interaction (PPI) networks and functional enrichment. MR analysis selected DEGs for further evaluation using support vector machine-recursive feature elimination (SVM-RFE), with genes exhibiting high differential expression and an area under the curve (AUC) > 0.7 considered as candidate biomarkers. Among 836 DEGs, the PPI network revealed complex interactions, and functional enrichment highlighted significant involvement of the PI3K-AKT and MAPK signaling pathways. MR analysis linked 113 DEGs to glaucoma, with 57 genes showing consistent expression trends. SVM-RFE identified six signature genes, among which ATP6V0D1 and FAM89B emerged as robust biomarkers (AUC > 0.7). Molecular regulatory network analysis and drug prediction analysis further revealed potential mechanisms and compounds targeting these biomarkers, providing new therapeutic avenues for glaucoma. Experimental validation confirmed that ATP6V0D1 and FAM89B were significantly downregulated under both mechanical and swelling stress conditions, with concurrent suppression of the PI3K/AKT pathway. In conclusion, ATP6V0D1 and FAM89B are promising biomarkers for glaucoma, offering potential applications in diagnosis, treatment, and advancing the understanding of glaucoma pathogenesis.
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessIdentifying diagnostic biomarkers for glaucoma based on transcriptome combined with Mendelian randomization
Glaucoma poses a significant global health challenge, yet reliable biomarkers for its diagnosis and treatment remain scarce. This study employed Mendelian randomization (MR) and bioinformatics approaches to identify potential biomarkers for glaucoma. Using the GSE9944 dataset, differentially expressed genes (DEGs) were identified and analyzed through protein-protein interaction (PPI) networks and functional enrichment. MR analysis selected DEGs for further evaluation using support vector machine-recursive feature elimination (SVM-RFE), with genes exhibiting high differential expression and an area under the curve (AUC) > 0.7 considered as candidate biomarkers. Among 836 DEGs, the PPI network revealed complex interactions, and functional enrichment highlighted significant involvement of the PI3K-AKT and MAPK signaling pathways. MR analysis linked 113 DEGs to glaucoma, with 57 genes showing consistent expression trends. SVM-RFE identified six signature genes, among which ATP6V0D1 and FAM89B emerged as robust biomarkers (AUC > 0.7). Molecular regulatory network analysis and drug prediction analysis further revealed potential mechanisms and compounds targeting these biomarkers, providing new therapeutic avenues for glaucoma. Experimental validation confirmed that ATP6V0D1 and FAM89B were significantly downregulated under both mechanical and swelling stress conditions, with concurrent suppression of the PI3K/AKT pathway. In conclusion, ATP6V0D1 and FAM89B are promising biomarkers for glaucoma, offering potential applications in diagnosis, treatment, and advancing the understanding of glaucoma pathogenesis.
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Diabetes Research
- Vol. 2024 (1) , 2920694
Identification and Validation of the Pyroptosis‐Related Hub Gene Signature and the Associated Regulation Axis in Diabetic Keratopathy
Background. Diabetic keratopathy (DK) poses a significant challenge in diabetes mellitus, yet its molecular pathways and effective treatments remain elusive. The aim of our research was to explore the pyroptosis‐related genes in the corneal epithelium of the streptozocin‐induced diabetic rats. Methods. After sixteen weeks of streptozocin intraperitoneal injection, corneal epithelium from three diabetic rats and three normal groups underwent whole‐transcriptome sequencing. An integrated bioinformatics pipeline, including differentially expressed gene (DEG) identification, enrichment analysis, protein‐protein interaction (PPI) network, coexpression, drug prediction, and immune deconvolution analyses, identified hub genes and key drivers in DK pathogenesis. These hub genes were subsequently validated in vivo through RT‐qPCR. Results. A total of 459 DEGs were screened out from the diabetic group and nondiabetic controls. Gene Set Enrichment Analysis highlighted significant enrichment of the NOD‐like receptor, Toll‐like receptor, and NF‐kappa B signaling pathways. Intersection of DEGs and pyroptosis‐related datasets showed 33 differentially expressed pyroptosis‐related genes (DEPRGs) associated with pathways such as IL‐17, NOD‐like receptor, TNF, and Toll‐like receptor signaling. A competing endogenous RNA network comprising 16 DEPRGs, 22 lncRNAs, 13 miRNAs, and 3 circRNAs was constructed. After PPI network, five hub genes (Nfkb1, Casp8, Traf6, Ptgs2, and Il18) were identified as upregulated in the diabetic group, and their expression was validated by RT‐qPCR in streptozocin‐induced rats. Immune infiltration characterization showed that diabetic corneas owned a higher proportion of resting mast cells, activated NK cells, and memory‐resting CD4 T cells. Finally, several small compounds including all‐trans‐retinoic acid, Chaihu Shugan San, dexamethasone, and resveratrol were suggested as potential therapies targeting these hub genes for DK. Conclusions. The identified and validated hub genes, Nfkb1, Casp8, Traf6, Ptgs2, and Il18, may play crucial roles in DK pathogenesis and serve as therapeutic targets.
- 1 January 2024
- Published by Wiley in Journal of Diabetes Research
- Vol. 2024 (1) , 2920694
Open AccessIdentification and Validation of the Pyroptosis‐Related Hub Gene Signature and the Associated Regulation Axis in Diabetic Keratopathy
Background. Diabetic keratopathy (DK) poses a significant challenge in diabetes mellitus, yet its molecular pathways and effective treatments remain elusive. The aim of our research was to explore the pyroptosis‐related genes in the corneal epithelium of the streptozocin‐induced diabetic rats. Methods. After sixteen weeks of streptozocin intraperitoneal injection, corneal epithelium from three diabetic rats and three normal groups underwent whole‐transcriptome sequencing. An integrated bioinformatics pipeline, including differentially expressed gene (DEG) identification, enrichment analysis, protein‐protein interaction (PPI) network, coexpression, drug prediction, and immune deconvolution analyses, identified hub genes and key drivers in DK pathogenesis. These hub genes were subsequently validated in vivo through RT‐qPCR. Results. A total of 459 DEGs were screened out from the diabetic group and nondiabetic controls. Gene Set Enrichment Analysis highlighted significant enrichment of the NOD‐like receptor, Toll‐like receptor, and NF‐kappa B signaling pathways. Intersection of DEGs and pyroptosis‐related datasets showed 33 differentially expressed pyroptosis‐related genes (DEPRGs) associated with pathways such as IL‐17, NOD‐like receptor, TNF, and Toll‐like receptor signaling. A competing endogenous RNA network comprising 16 DEPRGs, 22 lncRNAs, 13 miRNAs, and 3 circRNAs was constructed. After PPI network, five hub genes (Nfkb1, Casp8, Traf6, Ptgs2, and Il18) were identified as upregulated in the diabetic group, and their expression was validated by RT‐qPCR in streptozocin‐induced rats. Immune infiltration characterization showed that diabetic corneas owned a higher proportion of resting mast cells, activated NK cells, and memory‐resting CD4 T cells. Finally, several small compounds including all‐trans‐retinoic acid, Chaihu Shugan San, dexamethasone, and resveratrol were suggested as potential therapies targeting these hub genes for DK. Conclusions. The identified and validated hub genes, Nfkb1, Casp8, Traf6, Ptgs2, and Il18, may play crucial roles in DK pathogenesis and serve as therapeutic targets.
- 1 October 2021
- Published by Elsevier in Experimental Cell Research
- Vol. 407 (1) , 112792
Protective effects of intravitreal administration of mesenchymal stem cell-derived exosomes in an experimental model of optic nerve injury
- 1 October 2021
- Published by Elsevier in Experimental Cell Research
- Vol. 407 (1) , 112792
Protective effects of intravitreal administration of mesenchymal stem cell-derived exosomes in an experimental model of optic nerve injury
- Open Access
- 1 July 2020
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 61 (8) , 12
Exploring the Molecular Mechanisms of Pterygium by Constructing lncRNA–miRNA–mRNA Regulatory Network
Purpose: This research explores the aberrant expression of the long non-coding RNA (lncRNA), microRNA (miRNA), and messenger RNA (mRNA) in pterygium. A competitive endogenous RNA (ceRNA) network was constructed to elucidate the molecular mechanisms in pterygium. Methods: We obtained the differentially expressed mRNAs based on three datasets (GSE2513, GSE51995, and GSE83627), and summarized the differentially expressed miRNAs (DEmiRs) and differentially expressed lncRNAs (DELs) data by published literature. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, protein-protein interaction (PPI), and gene set enrichment analysis (GSEA) analysis were performed. DEmiRs were verified in GSE21346, and the regulatory network of hub mRNAs, DELs, and DEmiRs were constructed. Results: Overall, 40 upregulated and 40 downregulated differentially expressed genes (DEGs) were obtained. The KEGG enrichment showed the DEGs mainly involved in extracellular matrix (ECM)-receptor interaction, focal adhesion, and PI3K-Akt signaling pathway. The GSEA results showed that cornification, keratinization, and cornified envelope were significantly enriched. The validation outcome confirmed six upregulated DEmiRs (miR-766-3p, miR-184, miR-143-3p, miR-138-5p, miR-518b, and miR-1236-3p) and two downregulated DEmiRs (miR-200b-3p and miR-200a-3p). Then, a ceRNA regulatory network was constructed with 22 upregulated and 15 downregulated DEmiRs, 4 downregulated DELs, and 26 upregulated and 33 downregulated DEGs. The network showed that lncRNA SNHG1/miR-766-3p/FOS and some miRNA-mRNA axes were dysregulated in pterygium. Conclusions: Our study provides a novel perspective on the regulatory mechanism of pterygium, and lncRNA SNHG1/miR-766-3p/FOS may contribute to pterygium development.
- 1 July 2020
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 61 (8) , 12
Open AccessExploring the Molecular Mechanisms of Pterygium by Constructing lncRNA–miRNA–mRNA Regulatory Network
Purpose: This research explores the aberrant expression of the long non-coding RNA (lncRNA), microRNA (miRNA), and messenger RNA (mRNA) in pterygium. A competitive endogenous RNA (ceRNA) network was constructed to elucidate the molecular mechanisms in pterygium. Methods: We obtained the differentially expressed mRNAs based on three datasets (GSE2513, GSE51995, and GSE83627), and summarized the differentially expressed miRNAs (DEmiRs) and differentially expressed lncRNAs (DELs) data by published literature. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, protein-protein interaction (PPI), and gene set enrichment analysis (GSEA) analysis were performed. DEmiRs were verified in GSE21346, and the regulatory network of hub mRNAs, DELs, and DEmiRs were constructed. Results: Overall, 40 upregulated and 40 downregulated differentially expressed genes (DEGs) were obtained. The KEGG enrichment showed the DEGs mainly involved in extracellular matrix (ECM)-receptor interaction, focal adhesion, and PI3K-Akt signaling pathway. The GSEA results showed that cornification, keratinization, and cornified envelope were significantly enriched. The validation outcome confirmed six upregulated DEmiRs (miR-766-3p, miR-184, miR-143-3p, miR-138-5p, miR-518b, and miR-1236-3p) and two downregulated DEmiRs (miR-200b-3p and miR-200a-3p). Then, a ceRNA regulatory network was constructed with 22 upregulated and 15 downregulated DEmiRs, 4 downregulated DELs, and 26 upregulated and 33 downregulated DEGs. The network showed that lncRNA SNHG1/miR-766-3p/FOS and some miRNA-mRNA axes were dysregulated in pterygium. Conclusions: Our study provides a novel perspective on the regulatory mechanism of pterygium, and lncRNA SNHG1/miR-766-3p/FOS may contribute to pterygium development.
- Open Access
- 14 May 2019
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 14 (1) , 13
PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma
To evaluate the correlation of serum PIVKA-II levels and development of portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) patients. One hundred and twenty-three patients with newly diagnosed HCC were included in this study between March 2016 and October 2018. Thirty-five of these patients were detected with PVTT and all subjects were randomly divided to analysis group (N = 73) and validation (N = 50) group. Serum levels of PIVKA-II, laboratory tests including serum aspartate aminotransferase, total bilirubin, platelet count, albumin levels were demonstrated in all the patients. T-test, chi-squared test and logistic regression was used for analyzing data. Diagnostic efficiency and cut-off value of PIVKA-II in PVTT development of HCC patients were calculated using receiver operator curve (ROC) analysis. Serum level of PIVKA-II in HCC patients with PVTT was significantly higher than that in HCC patients without PVTT (995.8 mAU/ml vs 94.87 mAU/ml; P = 0.003), as well as D-dimer levels (2.12 mg/L vs 0.56 mg/L P = 0.001). Univariate analysis showed that high serum D-dimer level was an independent risk factor for development of PVTT (OR = 1.22, 95%CI 1.02–1.45). ROC curve showed that among analysis group, the area under ROC curve (AUROC) of PIVKA-II was 0.73 (95%CI 0.59–0.86). For the detection of PVTT in HCC, PIVKA-II had a sensitivity of 83.7% and a specificity of 69.2% at a cutoff of 221.26 mAU/ml, which had a sensitivity of 85.71% and a specificity of 55.56% in validation group, respectively. Serum PIVKA-II level is a potential marker for diagnosis of PVTT in HCC patients, which may guide therapeutic strategy and assessment of tumor prognosis of HCC.
- 14 May 2019
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 14 (1) , 13
Open AccessPIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma
To evaluate the correlation of serum PIVKA-II levels and development of portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) patients. One hundred and twenty-three patients with newly diagnosed HCC were included in this study between March 2016 and October 2018. Thirty-five of these patients were detected with PVTT and all subjects were randomly divided to analysis group (N = 73) and validation (N = 50) group. Serum levels of PIVKA-II, laboratory tests including serum aspartate aminotransferase, total bilirubin, platelet count, albumin levels were demonstrated in all the patients. T-test, chi-squared test and logistic regression was used for analyzing data. Diagnostic efficiency and cut-off value of PIVKA-II in PVTT development of HCC patients were calculated using receiver operator curve (ROC) analysis. Serum level of PIVKA-II in HCC patients with PVTT was significantly higher than that in HCC patients without PVTT (995.8 mAU/ml vs 94.87 mAU/ml; P = 0.003), as well as D-dimer levels (2.12 mg/L vs 0.56 mg/L P = 0.001). Univariate analysis showed that high serum D-dimer level was an independent risk factor for development of PVTT (OR = 1.22, 95%CI 1.02–1.45). ROC curve showed that among analysis group, the area under ROC curve (AUROC) of PIVKA-II was 0.73 (95%CI 0.59–0.86). For the detection of PVTT in HCC, PIVKA-II had a sensitivity of 83.7% and a specificity of 69.2% at a cutoff of 221.26 mAU/ml, which had a sensitivity of 85.71% and a specificity of 55.56% in validation group, respectively. Serum PIVKA-II level is a potential marker for diagnosis of PVTT in HCC patients, which may guide therapeutic strategy and assessment of tumor prognosis of HCC.
- Open Access
- 12 December 2018
- Published by Wiley in Journal of Ophthalmology
- Vol. 2018, 1-10
Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis
Purpose. Numerous medical strategies have been proposed for the treatment of thyroid eye disease (TED); however, the best methods for standard treatment are still a matter of controversy. The purpose of this network meta-analysis was to integrate previous evidence to create hierarchies of comparative efficacy of eleven commonly used medical treatments for TED. Methods. A comprehensive search of electronic scientific literature databases was performed and the data from randomized controlled trials (RCTs) comparing treatment outcomes for patients with active TED were selected. Treatment strategies included in this network meta-analysis were intravenous glucocorticoids (IVGC), oral glucocorticoids (OGC), orbital injection of glucocorticoids (OIGC), orbital radiotherapy (OR), intravenous glucocorticoids combined with orbital radiotherapy (IVGC + OR), oral glucocorticoids combined with orbital radiotherapy (OGC + OR), rituximab (RTX), somatostatin analogs, intravenous immunoglobulin (IVIG), teprotumumab, and cyclosporine. The outcomes were response rate, mean difference in proptosis reduction, and reduction in disease activity. A random-effects network meta-analysis using a frequent method was conducted in STATA. Results. Twenty-three studies comprising a total of 1047 patients were included in the analysis. Inconsistency plots showed heterogeneity in the IVGC-Placebo-RTX loop to some extent (RoR = 8.029, ). Rankings of response rates were as follows: IVGC + OR, teprotumumab, IVGC, OGC + OR, RTX, OIGC, OR, IVIG, OGC, somatostatin, placebo, and cyclosporine. The rank probability analysis of proptosis reduction showed that teprotumumab was the most effective, followed by IVGC, IVGC + OR, OIGC, OGC, OGC + OR, OR, somatostatin, cyclosporine, and placebo. Conclusions. IVGC, alone or combination with OR, and teprotumumab should be preferred as the most effective strategies for active moderate to severe TED. Teprotumumab showed profound effect on proptosis reduction. OIGC, OR, and somatostatin analogs showed some statistical benefit and can be employed as second-line treatment strategies. RTX is a promising biologic agent, but more RCTs are required to define its appropriate role in treating TED.- 12 December 2018
- Published by Wiley in Journal of Ophthalmology
- Vol. 2018, 1-10
Open AccessComparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis
Purpose. Numerous medical strategies have been proposed for the treatment of thyroid eye disease (TED); however, the best methods for standard treatment are still a matter of controversy. The purpose of this network meta-analysis was to integrate previous evidence to create hierarchies of comparative efficacy of eleven commonly used medical treatments for TED. Methods. A comprehensive search of electronic scientific literature databases was performed and the data from randomized controlled trials (RCTs) comparing treatment outcomes for patients with active TED were selected. Treatment strategies included in this network meta-analysis were intravenous glucocorticoids (IVGC), oral glucocorticoids (OGC), orbital injection of glucocorticoids (OIGC), orbital radiotherapy (OR), intravenous glucocorticoids combined with orbital radiotherapy (IVGC + OR), oral glucocorticoids combined with orbital radiotherapy (OGC + OR), rituximab (RTX), somatostatin analogs, intravenous immunoglobulin (IVIG), teprotumumab, and cyclosporine. The outcomes were response rate, mean difference in proptosis reduction, and reduction in disease activity. A random-effects network meta-analysis using a frequent method was conducted in STATA. Results. Twenty-three studies comprising a total of 1047 patients were included in the analysis. Inconsistency plots showed heterogeneity in the IVGC-Placebo-RTX loop to some extent (RoR = 8.029, ). Rankings of response rates were as follows: IVGC + OR, teprotumumab, IVGC, OGC + OR, RTX, OIGC, OR, IVIG, OGC, somatostatin, placebo, and cyclosporine. The rank probability analysis of proptosis reduction showed that teprotumumab was the most effective, followed by IVGC, IVGC + OR, OIGC, OGC, OGC + OR, OR, somatostatin, cyclosporine, and placebo. Conclusions. IVGC, alone or combination with OR, and teprotumumab should be preferred as the most effective strategies for active moderate to severe TED. Teprotumumab showed profound effect on proptosis reduction. OIGC, OR, and somatostatin analogs showed some statistical benefit and can be employed as second-line treatment strategies. RTX is a promising biologic agent, but more RCTs are required to define its appropriate role in treating TED. - Open Access
- 1 December 2018
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 367 (3) , 405-413
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma
Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase involved in leukocyte recruitment and activation. Activation of PI3Kδ has been linked to airway inflammation and asthma pathogenesis. This randomised, double-blind, placebo-controlled, crossover study investigated the efficacy, safety, tolerability and pharmacokinetics of a PI3Kδ inhibitor, nemiralisib (GSK2269557), in patients with persistent, uncontrolled asthma. Patients (n=50) received once-daily inhaled nemiralisib (1000 µg) or placebo for 28 days, with a crossover to the alternative treatment following a 4-week washout period. Spirometry demonstrated no discernible difference in trough forced expiratory volume in 1 second (FEV1) from baseline (adjusted posterior median 7 mL; 95% credible interval -83 mL, 102 mL) between nemiralisib and placebo treatment at Day 28 (primary endpoint). These results were supported by most secondary endpoints, including weighted mean FEV1 (0-4 h) and change in trough forced vital capacity at Day 28. Nemiralisib was generally well-tolerated, with few side effects except for post-inhalation cough (nemiralisib: 35%; placebo: 9%). At Day 28, sputum interleukin (IL)-5, IL-13, IL-6 and IL-8 levels were reduced by a median of 17%, 7%, 15% and 8%, respectively, when comparing nemiralisib with placebo (n=15 [IL-5, IL-8] or 16 [IL-6, IL-13]; posterior probability of a true ratio >0%: 78%, 64%, 76% and 63%, respectively). These results suggest that nemiralisib inhibited PI3Kδ locally; however, this did not translate into meaningful clinical improvement. Further studies will investigate the potential efficacy of nemiralisib in patients with asthma with other specific more severe phenotypes, including those who are colonised with bacteria and frequently exacerbate.
- 1 December 2018
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 367 (3) , 405-413
Open AccessA Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma
Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase involved in leukocyte recruitment and activation. Activation of PI3Kδ has been linked to airway inflammation and asthma pathogenesis. This randomised, double-blind, placebo-controlled, crossover study investigated the efficacy, safety, tolerability and pharmacokinetics of a PI3Kδ inhibitor, nemiralisib (GSK2269557), in patients with persistent, uncontrolled asthma. Patients (n=50) received once-daily inhaled nemiralisib (1000 µg) or placebo for 28 days, with a crossover to the alternative treatment following a 4-week washout period. Spirometry demonstrated no discernible difference in trough forced expiratory volume in 1 second (FEV1) from baseline (adjusted posterior median 7 mL; 95% credible interval -83 mL, 102 mL) between nemiralisib and placebo treatment at Day 28 (primary endpoint). These results were supported by most secondary endpoints, including weighted mean FEV1 (0-4 h) and change in trough forced vital capacity at Day 28. Nemiralisib was generally well-tolerated, with few side effects except for post-inhalation cough (nemiralisib: 35%; placebo: 9%). At Day 28, sputum interleukin (IL)-5, IL-13, IL-6 and IL-8 levels were reduced by a median of 17%, 7%, 15% and 8%, respectively, when comparing nemiralisib with placebo (n=15 [IL-5, IL-8] or 16 [IL-6, IL-13]; posterior probability of a true ratio >0%: 78%, 64%, 76% and 63%, respectively). These results suggest that nemiralisib inhibited PI3Kδ locally; however, this did not translate into meaningful clinical improvement. Further studies will investigate the potential efficacy of nemiralisib in patients with asthma with other specific more severe phenotypes, including those who are colonised with bacteria and frequently exacerbate.
- Open Access
- 8 November 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (11) , e0206811
Substrate-independent immunomodulatory characteristics of mesenchymal stem cells in three-dimensional culture
Mesenchymal stem cells (MSCs) play important roles in tissue regeneration, and multi-lineage differentiation and immunomodulation are two major characteristics of MSCs that are utilized in stem cell therapy. MSCs in vivo have a markedly different three-dimensional (3D) niche compared to the traditional two-dimensional (2D) culture in vitro. A 3D scaffold is predicted to provide an artificial 3D environment similar to the in vivo environment. Significant changes in MSC differentiation are shown to be occurred when under 3D culture. However, the immunomodulatory characteristics of MSCs under 3D culture remain unknown. In this study, 3D culture systems were constructed using different substrates to evaluate the common immunomodulatory characteristics of MSCs. Compared to the MSCs under 2D culture, the MSCs under 3D culture, which had higher stemness and maintained cell phenotype, showed altered immunophenotypic pattern. Gene expression profile analysis at mRNA and protein level detected by gene chip and protein chip, respectively, further revealed the difference between 3D cultured MSCs and 2D cultured MSCs, which was mainly concentrated in the immunoregulation related aspects. Moreover, the immunoregulatory role of 3D culture was confirmed by our immunosuppressive experiments. These findings demonstrated that the immunomodulatory capacities of MSCs were enhanced by the 3D geometry of substrates.
- 8 November 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (11) , e0206811
Open AccessSubstrate-independent immunomodulatory characteristics of mesenchymal stem cells in three-dimensional culture
Mesenchymal stem cells (MSCs) play important roles in tissue regeneration, and multi-lineage differentiation and immunomodulation are two major characteristics of MSCs that are utilized in stem cell therapy. MSCs in vivo have a markedly different three-dimensional (3D) niche compared to the traditional two-dimensional (2D) culture in vitro. A 3D scaffold is predicted to provide an artificial 3D environment similar to the in vivo environment. Significant changes in MSC differentiation are shown to be occurred when under 3D culture. However, the immunomodulatory characteristics of MSCs under 3D culture remain unknown. In this study, 3D culture systems were constructed using different substrates to evaluate the common immunomodulatory characteristics of MSCs. Compared to the MSCs under 2D culture, the MSCs under 3D culture, which had higher stemness and maintained cell phenotype, showed altered immunophenotypic pattern. Gene expression profile analysis at mRNA and protein level detected by gene chip and protein chip, respectively, further revealed the difference between 3D cultured MSCs and 2D cultured MSCs, which was mainly concentrated in the immunoregulation related aspects. Moreover, the immunoregulatory role of 3D culture was confirmed by our immunosuppressive experiments. These findings demonstrated that the immunomodulatory capacities of MSCs were enhanced by the 3D geometry of substrates.